FDA Grants Orphan Drug Designation to HQP1351 for Chronic Myeloid Leukemia

The FDA granted orphan drug designation to Ascentage Pharma ’s HQP1351 for the treatment of chronic myeloid leukemia.

Source: CancerNetwork - May 5, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news